KING OF PRUSSIA, PA — Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY), announced that The Lancet recently published results from the Phase 3 VANGUARD study evaluating garadacimab (CSL312) as a once-monthly, prophylactic treatment for attacks due to hereditary angioedema (HAE). The Lancet paper provides detailed data on the Phase 3 study, which were recently presented during the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. The study met its primary and secondary endpoints, demonstrating that monthly subcutaneous injections of garadacimab significantly reduced the attack rate compared to placebo in patients with HAE.
During the double-blind, randomized, placebo-controlled, multicenter, parallel-group study, patients taking garadacimab (N=39) experienced a statistically lower monthly attack rate compared to placebo over the 6-month treatment period (p< 0.0001). The mean monthly attack rate was 0.27 for patients treated with garadacimab versus 2.01 for those on placebo (N=25), with a median monthly attack rate of 0 for patients treated with garadacimab versus 1.35 for placebo, resulting in an attack rate reduction in means of 86.5% versus placebo and an attack rate reduction in medians of 100% versus placebo. The attack rate reduction compared with placebo after adjusting for baseline attack rate was 89.2%. Notably, early onset of protection with garadacimab was evident from the first dose, with nearly three-quarters of patients being attack-free within the first 3 months, and sustained efficacy over the second 3-month period.
In addition, the results published in The Lancet show patients treated with garadacimab once a month experienced a reduction in the number of time-normalized moderate or severe HAE attacks and a reduction in the number of HAE attacks requiring on-demand rescue medication compared to patients who received placebo. Garadacimab also demonstrated improvements in patient-reported outcomes with 81.6% of garadacimab patients reporting a ‘good’ or better Subject’s Global Assessment of Response to Therapy (SGART) response in the six-month trial compared to 33.3% of patients receiving placebo. The study also showed that garadacimab demonstrated a favorable safety profile with a similar frequency of treatment-emergent adverse events across garadacimab and placebo arms. The most common TEAEs in patients treated with garadacimab were upper respiratory infection, nasopharyngitis, and headache. There were no adverse events of bleeding or thrombosis.
“Despite the availability of effective preventative treatments for HAE, patients still experience breakthrough attacks and a high burden of disease, and there is a need for new treatment options that offer more convenience, choice and control,” said Catherine Milch, Vice President R&D Immunology, CSL. “Based on the data published in The Lancet, we believe garadacimab has the potential to become a transformative first-in-class therapy, providing a new option where there is significant unmet need. The development of garadacimab reflects our commitment to providing life changing medicines for patients with HAE and for the physicians who treat them.”
The Lancet article titled, “Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial,” was published online on February 28, 2023. CSL anticipates global regulatory submissions later this year for approval of garadacimab.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.
Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.